Acumen Pharmaceuticals, Inc. ( (ABOS) ) has released its Q3 earnings. Here is a breakdown of the information Acumen Pharmaceuticals, Inc.

Revenue missed analyst estimates by 24%. Earnings per share (EPS) also missed analyst estimates by 64%. Looking ahead, ...

Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene therapy to ...

For Q2, the company’s revenue from the Indian market rose 13.9 per cent to Rs 1,281.7 crore, contributing 37 per cent to ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...

SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial ...

Tempest Therapeutics (TPST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Recent developments driving growth in this area make the advanced, AI-supported digitization of pharma pipelines inevitable.

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...

Glenmark Pharma continued to benefit from its strong position in key chronic therapy areas, including respiratory and dermatology therapeutics, according to its latest, opens new tab annual report.

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good afternoon, and thank you for standing by. At this time, I’d ...